Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Sep 26;9(9):CD007524.
doi: 10.1002/14651858.CD007524.pub5.

Increased versus stable doses of inhaled corticosteroids for exacerbations of chronic asthma in adults and children

Kayleigh M Kew #  1 , Ella Flemyng #  2 , Bradley S Quon  3 , Clarus Leung  3
Affiliations

Increased versus stable doses of inhaled corticosteroids for exacerbations of chronic asthma in adults and children

Kayleigh M Kew et al. Cochrane Database Syst Rev. .

Abstract

Background: People with asthma may experience exacerbations, or 'attacks', during which their symptoms worsen and additional treatment is required. Written action plans sometimes advocate a short-term increase in the dose of inhaled corticosteroids (ICS) at the first sign of an exacerbation to reduce the severity of the attack and to prevent the need for oral steroids or hospital admission.

Objectives: To compare the clinical effectiveness and safety of increased versus stable doses of ICS as part of a patient-initiated action plan for the home management of exacerbations in children and adults with persistent asthma.

Search methods: We searched the Cochrane Airways Group Specialised Register, which is derived from searches of the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase, and CINAHL (Cumulative Index to Nursing and Allied Health Literature), and handsearched abstracts to 20 December 2021. We also searched major trial registries for ongoing trials.

Selection criteria: We included parallel and cross-over randomised controlled trials (RCTs) that allocated people with persistent asthma to take a blinded inhaler in the event of an exacerbation which either increased their daily dose of ICS or kept it stable (placebo).

Data collection and analysis: Two review authors independently selected trials, assessed quality, and extracted data. We reassessed risk of bias for all studies at the result level using the revised risk of bias tool for RCTs (Risk of Bias 2), and employed the GRADE approach to assess our confidence in the synthesised effect estimates. The primary outcome was treatment failure, defined as the need for rescue oral steroids in the randomised population. Secondary outcomes were treatment failure in the subset who initiated the study inhaler (treated population), unscheduled physician visits, unscheduled acute care, emergency department or hospital visits, serious and non-serious adverse events, and duration of exacerbation.

Main results: This review update added a new study that increased the number of people in the primary analysis from 1520 to 1774, and incorporates the most up-to-date methods to assess the likely impact of bias within the meta-analyses. The updated review now includes nine RCTs (1923 participants; seven parallel and two cross-over) conducted in Europe, North America, and Australasia and published between 1998 and 2018. Five studies evaluated adult populations (n = 1247; ≥ 15 years), and four studies evaluated child or adolescent populations (n = 676; < 15 years). All study participants had mild to moderate asthma. Studies varied in the dose of maintenance ICS, age, fold increase of ICS in the event of an exacerbation, criteria for initiating the study inhaler, and allowed medications. Approximately 50% of randomised participants initiated the study inhaler (range 23% to 100%), and the included studies reported treatment failure in a variety of ways, meaning assumptions were required to permit the combining of data. Participants randomised to increase their ICS dose at the first signs of an exacerbation had similar odds of needing rescue oral corticosteroids to those randomised to a placebo inhaler (odds ratio (OR) 0.97, 95% confidence interval (CI) 0.76 to 1.25; 8 studies; 1774 participants; I2 = 0%; moderate quality evidence). We could draw no firm conclusions from subgroup analyses conducted to investigate the impact of age, time to treatment initiation, baseline dose, smoking history, and fold increase of ICS on the primary outcome. Results for the same outcome in the subset of participants who initiated the study inhaler were unchanged from the previous version, which provides a different point estimate with very low confidence due to heterogeneity, imprecision, and risk of bias (OR 0.84, 95% CI 0.54 to 1.30; 7 studies; 766 participants; I2 = 42%; random-effects model). Confidence was reduced due to risk of bias and assumptions that had to be made to include study data in the intention-to-treat and treated-population analyses. Sensitivity analyses that tested the impact of assumptions made for synthesis and to exclude cross-over studies, studies at overall high risk of bias, and those with commercial funding did not change our conclusions. Pooled effects for unscheduled physician visits, unscheduled acute care, emergency department or hospital visits, and duration of exacerbation made it very difficult to determine where the true effect may lie, and confidence was reduced by risk of bias. Point estimates for both serious and non-serious adverse events favoured keeping ICS stable, but imprecision and risk of bias due to missing data and outcome measurement and reporting reduced our confidence in the effects (serious adverse events: OR 1.69, 95% CI 0.77 to 3.71; 2 studies; 394 participants; I² = 0%; non-serious adverse events: OR 2.15, 95% CI 0.68 to 6.73; 2 studies; 142 participants; I² = 0%).

Authors' conclusions: Evidence from double-blind trials of adults and children with mild to moderate asthma suggests there is unlikely to be an important reduction in the need for oral steroids from increasing a patient's ICS dose at the first sign of an exacerbation. Other clinically important benefits and potential harms of increased doses of ICS compared with keeping the dose stable cannot be ruled out due to wide confidence intervals, risk of bias in the trials, and assumptions that had to be made for synthesis. Included studies conducted between 1998 and 2018 reflect evolving clinical practice and study methods, and the data do not support thorough investigation of effect modifiers such as baseline dose, fold increase, asthma severity and timing. The review does not include recent evidence from pragmatic, unblinded studies showing benefits of larger dose increases in those with poorly controlled asthma. A systematic review is warranted to examine the differences between the blinded and unblinded trials using robust methods for assessing risk of bias to present the most complete view of the evidence for decision makers.

Trial registration: ClinicalTrials.gov NCT00394329 NCT03769090.

PubMed Disclaimer

Conflict of interest statement

Kayleigh Kew: former employee of the Cochrane Central Executive Team (2020 to 2021), during which time most of the work for the update was completed, and former employee of the Cochrane Airways editorial team (2012 to 2016). No commercial or non‐commercial conflicts of interest relevant to this review.

Ella Flemyng: employee of the Cochrane Central Executive Team. No commercial or non‐commercial conflicts of interest relevant to this review.

Bradley Quon: none known

Clarus Leung: none known

Figures

1
1
Study flow diagram.
1.1
1.1. Analysis
Comparison 1: Increased versus stable doses of ICS, Outcome 1: Treatment failure: need for systemic corticosteroids (primary outcome, all randomised participants)
1.2
1.2. Analysis
Comparison 1: Increased versus stable doses of ICS, Outcome 2: Treatment failure: need for systemic corticosteroids (of those starting inhaler)
1.3
1.3. Analysis
Comparison 1: Increased versus stable doses of ICS, Outcome 3: Unscheduled physician visits
1.4
1.4. Analysis
Comparison 1: Increased versus stable doses of ICS, Outcome 4: Unscheduled acute care, ED visit, or hospital admission
1.5
1.5. Analysis
Comparison 1: Increased versus stable doses of ICS, Outcome 5: Serious and non‐serious adverse events
1.6
1.6. Analysis
Comparison 1: Increased versus stable doses of ICS, Outcome 6: Duration of exacerbation
2.1
2.1. Analysis
Comparison 2: Primary outcome subgroup and sensitivity analyses, Outcome 1: Subgrouped by age
2.2
2.2. Analysis
Comparison 2: Primary outcome subgroup and sensitivity analyses, Outcome 2: Subgrouped by time to treatment initiation
2.3
2.3. Analysis
Comparison 2: Primary outcome subgroup and sensitivity analyses, Outcome 3: Subgrouped by maintenance ICS dose
2.4
2.4. Analysis
Comparison 2: Primary outcome subgroup and sensitivity analyses, Outcome 4: Subgrouped by ICS dose during exacerbation
2.5
2.5. Analysis
Comparison 2: Primary outcome subgroup and sensitivity analyses, Outcome 5: Subgrouped by ICS fold increase
2.6
2.6. Analysis
Comparison 2: Primary outcome subgroup and sensitivity analyses, Outcome 6: Sensitivity analysis: parallel‐group studies only
2.7
2.7. Analysis
Comparison 2: Primary outcome subgroup and sensitivity analyses, Outcome 7: Sensitivity analysis: removing studies at overall high risk of bias
2.8
2.8. Analysis
Comparison 2: Primary outcome subgroup and sensitivity analyses, Outcome 8: Sensitivity analysis: independently funded studies only
See this image and copyright information in PMC

Update of

Similar articles

See all similar articles

Cited by

References

References to studies included in this review

ACTRN12605000631606 {unpublished data only}ACTRN12605000631606
    1. ACTRN12605000631606. Treatment of acute exacerbations of asthma in children with a doubling of the usual inhaled corticosteroid (ICS) dose [A multicentre randomised controlled trial of treatment of acute exacerbations of asthma in children with a doubling of the usual inhaled corticosteroid (ICS) dose to identify efficacy of intervention ]. www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=630 (first received 13 September 2015).
FitzGerald 2004 {published data only}
    1. FitzGerald JM, Becker A, Sears MR, Mink S, Chung K, Lee J, et al. Doubling the dose of budesonide versus maintenance treatment in asthma exacerbations. Thorax 2004;59(7):550-6. [PMID: ] - PMC - PubMed
Foresi 2000 {published data only}
    1. Foresi A, Morelli MC, Catena E. Low-dose budesonide with the addition of an increased dose during exacerbations is effective in long-term asthma control. Chest 2000;117(2):440-6. [PMID: ] - PubMed
Garrett 1998 {published data only}
    1. Garrett J, Williams S, Wong C, Holdaway D. Treatment of acute asthmatic exacerbations with an increased dose of inhaled steroid. Archives of Disease in Childhood 1998;79(1):12-7. [PMID: ] - PMC - PubMed
Harrison 2004 {published data only}
    1. Harrison TW, Oborne J, Newton S, Tattersfield AE. Doubling the dose of inhaled corticosteroid to prevent asthma exacerbations: randomised controlled trial. Lancet 2004;363(9405):271-5. [PMID: ] - PubMed
Jackson 2018 {published data only}
    1. Jackson DJ, Bacharier LB, Mauger DT, Boehmer S, Beigelman A, Chmiel JF, et al. Quintupling inhaled glucocorticoids to prevent childhood asthma exacerbations. New England Journal of Medicine 2018;378(10):891-901. - PMC - PubMed
    1. NCT02066129. Step-up yellow zone inhaled corticosteroids to prevent exacerbations (STICS). clinicaltrials.gov/ct2/show/NCT02066129 (first received 19 February 2014).
Martinez 2011 {published data only}
    1. Martinez FD, Chinchilli VM, Morgan WJ, Boehmer SJ, Lemanske RF, Mauger DT, et al. Use of beclomethasone dipropionate as rescue treatment for children with mild persistent asthma (TREXA): a randomised, double-blind, placebo-controlled trial. Lancet 2011;377:650-7. [PMID: ] - PMC - PubMed
Oborne 2009 {published data only}
    1. Oborne J, Mortimer K, Hubbard RB, Tattersfield AE, Harrison TW. Quadrupling the dose of inhaled corticosteroid to prevent asthma exacerbations: a randomized, double blind, placebo controlled, parallel group, clinical trial. American Journal of Respiratory and Critical Care Medicine 2009;180(7):598-602. [PMID: ] - PubMed
Rice‐McDonald 2005 {published data only}
    1. Rice-McDonald G, Bowler S, Staines G, Mitchell C. Doubling daily inhaled corticosteroid dose is ineffective in mild to moderately severe attacks of asthma in adults. Internal Medicine Journal 2005;35(12):693-8. [PMID: ] - PubMed

References to studies excluded from this review

Bateman 2008 {published data only}
    1. Bateman ED, Cheung D, Lapa e Silva J, Göhring UM, Schäfer M, Engelstätter R. Randomized comparison of ciclesonide 160 and 640 μg/day in severe asthma. Pulmonary Pharmacology and Therapeutics 2008;21(3):489-98. [PMID: ] - PubMed
Boushey 2005 {published data only}
    1. Boushey HA, Sorkness CA, King TS, Sullivan SD, Fahy JV, Lazarus SC, et al. Daily versus as-needed corticosteroids for mild persistent asthma. New England Journal of Medicine 2005;352(15):1519-28. [PMID: ] - PubMed
Brand 2011 {published data only}
    1. Brand PL, Luz Garcia-Garcia M, Morison A, Vermeulen JH, Weber HC, Brand PLP. Ciclesonide in wheezy preschool children with a positive asthma predictive index or atopy. Respiratory Medicine 2011;105(11):1588-95. - PubMed
Bullard 1996 {published data only}
    1. Bullard MJ, Liaw SJ, Tsai YH, Min H. Early corticosteroid use in acute exacerbations of chronic airflow obstruction. American Journal of Emergency Medicine 1996;14(2):139-43. [PMID: ] - PubMed
Clearie 2010 {published data only}
    1. Clearie KL. Airway Challenges in Different Clinical Phenotypes and Their Relationship to Markers of Disease and Treatment [PhD thesis]. Dundee, UK: University of Dundee, 2010.
Condemi 1999 {published data only}
    1. Condemi JJ, Goldstein S, Kalberg C, Yancey S, Emmett A, Rickard K. The addition of salmeterol to fluticasone propionate versus increasing the dose of fluticasone propionate in patients with persistent asthma. Annals of Allergy, Asthma & Immunology 1999;82(4):383-9. [PMID: ] - PubMed
Connett 1993 {published data only}
    1. Connett G, Lenney W. Prevention of viral induced asthma attacks using inhaled budesonide. Archives of Disease in Childhood 1993;68(1):85-7. [PMID: ] - PMC - PubMed
Currie 2003 {published data only}
    1. Currie GP, Bates CE, Lee DK, Jackson CM, Lipworth BJ. Effects of fluticasone plus salmeterol versus twice the dose of fluticasone in asthmatic patients. European Journal of Clinical Pharmacology 2003;59(1):11-5. [PMID: ] - PubMed
De Benedictis 2005 {published data only}
    1. De Benedictis FM, Del Giudice MM, Vetrella M, Tressanti F, Tronci A, Testi R, et al. Nebulized fluticasone propionate vs. budesonide as adjunctive treatment in children with asthma exacerbation. Journal of Asthma 2005;42(5):331-6. [PMID: ] - PubMed
Devidayal 1999 {published data only}
    1. Devidayal, Singhi S, Kumar L, Jayshree M. Efficacy of nebulized budesonide compared to oral prednisolone in acute bronchial asthma. Acta Paediatrica 1999;88(8):835-40. [PMID: ] - PubMed
Farber 2016 {published data only}
    1. Farber HJ. POINT: is escalation of the inhaled corticosteroid dose appropriate for acute loss of asthma control in an attempt to reduce need for oral corticosteroids in children? Yes. Chest 2016;150(3):488-90. - PubMed
FitzGerald 2000 {published data only}
    1. FitzGerald JM, Shragge D, Haddon J, Jennings B, Math JLM, Bai T, et al. A randomized, controlled trial of high dose, inhaled budesonide versus oral prednisone in patients discharged from the emergency department following an acute asthma exacerbation. Canadian Respiratory Journal 2000;7(1):61-7. [PMID: ] - PubMed
Gilbert 2018 {published data only}
    1. Gilbert JA. Effect of increasing glucocorticoids on asthma exacerbations. Lancet Respiratory Medicine 2018;6(5):P328. - PubMed
Greening 1994 {published data only}
    1. Greening AP, Ind PW, Northfield M, Shaw G. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Lancet 1994;344(8917):219-24. [PMID: ] - PubMed
GSK 2005 {published data only}
    1. GlaxoSmithKline. A multicentre, double-blind, randomised, four-week, parallel-group comparison of inhaled fluticasone propionate and inhaled beclomethasone dipropionate in patients with severe asthma controlled by high-dose inhaled corticosteroids (FLIP04). www.gsk-clinicalstudyregister.com/study/FMS30049#rs (first received 17 December 2015).
Hanania 2020 {published data only}
    1. Hanania N, Kerwin E, Pavord I, Kerstjens H, Pascoe S, Peachey G, et al. Step-up to high dose fluticasone furoate in combination with long-acting bronchodilator in inadequately controlled asthma: the CAPTAIN study. Journal of Allergy and Clinical Immunology 2020;145(2):AB24.
Hedlin 1999 {published data only}
    1. Hedlin G, Svedmyr J, Ryden AC. Systemic effects of a short course of betamethasone compared with high-dose inhaled budesonide in early childhood asthma. Acta Paediatrica 1999;88(1):48-51. [PMID: ] - PubMed
Heinig 1999 {published data only}
    1. Heinig JH, Boulet LP, Croonenborghs L, Mollers MJ. The effect of high-dose fluticasone propionate and budesonide on lung function and asthma exacerbations in patients with severe asthma. Respiratory Medicine 1999;93(9):613-20. [PMID: ] - PubMed
Karpel 2007 {published data only}
    1. Karpel JP, Nayak A, Lumry W, Craig TJ, Kerwin E, Fish JE, et al. Inhaled mometasone furoate reduces oral prednisone usage and improves lung function in severe persistent asthma. Respiratory Medicine 2007;101(3):628-37. [PMID: ] - PubMed
La Rosa 1997 {published data only}
    1. La Rosa M, Ranno C, Mandair G, Barbato A, Biraghi M. Double-blind study of inhaled salbutamol versus salbutamol plus high-dose flunisolide in exacerbation of bronchial asthma: a pilot study. Pediatric Asthma, Allergy and Immunology 1997;11(1):23-30. [EMBASE: 1997208440]
Lee‐Wong 2002 {published data only}
    1. Lee-Wong M, Dayrit FM, Kohli AR, Acquah S, Mayo PH. Comparison of high-dose inhaled flunisolide to systemic corticosteroids in severe adult asthma. Chest 2002;122(4):1208-13. [PMID: ] - PubMed
Lemanske 2010 {published data only}
    1. Lemanske R, Mauger DT, Sorkness CA, Jackson DJ, Boehmer SJ, Martinez FD, et al. Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids. New England Journal of Medicine 2010;362(11):975-85. [DOI: 10.1056/NEJMoa1001278] - DOI - PMC - PubMed
Leuppi 2002 {published data only}
    1. Leuppi JD, Downie SR, Salome CM, Jenkins CR, Woolcock AJ. A single high dose of inhaled corticosteroids: a possible treatment of asthma exacerbations. Swiss Medical Weekly 2002;132(1-2):7-11. [PMID: ] - PubMed
Levy 1996 {published data only}
    1. Levy ML, Stevenson C, Maslen T. Comparison of short courses of oral prednisolone and fluticasone propionate in the treatment of adults with acute exacerbations of asthma in primary care. Thorax 1996;51(11):1087-92. [PMID: ] - PMC - PubMed
Manjra 2000 {published data only}
    1. Manjra AI, Price J, Lenney W, Hughes S, Barnacle H. Efficacy of nebulized fluticasone propionate compared with oral prednisolone in children with an acute exacerbation of asthma. Respiratory Medicine 2000;94(12):1206-14. [PMID: ] - PubMed
Matz 2001 {published data only}
    1. Matz J, Emmett A, Rickard K, Kalberg C. Addition of salmeterol to low-dose fluticasone versus higher-dose fluticasone: an analysis of asthma exacerbations. Journal of Allergy and Clinical Immunology 2001;107(5):783-9. [PMID: ] - PubMed
McKeever 2018 {published data only}
    1. Chung S, Zappetti D. Can quadrupling inhaled glucocorticoid dose during early asthma exacerbation reduce the need for systemic steroids or hospital admission? Clinical Pulmonary Medicine 2019;26(3):102-4.
    1. Maselli DJ, Peters JI. Quadrupling inhaled glucocorticoid dose for deteriorating asthma control reduced severe exacerbations. Annals of Internal Medicine 2018;168(12):JC65. - PubMed
    1. McKeever T, Mortimer K, Bradshaw L, Haydock R, Pavord I, Higgins B, et al. Temporarily quadrupling the dose of inhaled steroid to prevent asthma exacerbations: FAST. Health Technology Assessment 2018;22(70):1-82. - PMC - PubMed
    1. McKeever T, Mortimer K, Duley L, Bradshaw L, Swinden R, Skeggs A, et al. Late breaking abstract - can a self-management plan, which includes a four-fold increase in inhaled corticosteroid dose, reduce severe asthma exacerbations: a randomised, pragmatic trial. European Respiratory Journal 2017;50(Suppl 61):PA1367. [DOI: 10.1183/1393003.congress-2017.PA1367] - DOI
    1. McKeever T, Mortimer K, Wilson A, Walker S, Brightling C, Skeggs A, et al. Quadrupling inhaled glucocorticoid dose to abort asthma exacerbations. New England Journal of Medicine 2018;378(10):902-10. - PubMed
Milani 2004 {published data only}
    1. Milani GK, Rosario Filho NA, Riedi CA, Figueiredo BC. Nebulized budesonide to treat acute asthma in children. Jornal de Pediatria 2004;80(2):106-12. [EMBASE: 2006186583] - PubMed
Nana 1998 {published data only}
    1. Nana A, Youngchaiyud P, Charoenratanakul S, Boe J, Lofdahl C, Selroos O, et al. High-dose inhaled budesonide may substitute for oral therapy after an acute asthma attack. Journal of Asthma 1998;35(8):647-55. [PMID: ] - PubMed
NCT02995733 {published data only}
    1. NCT02995733. Patient empowered strategy to reduce asthma morbidity in highly impacted populations; PeRson EmPowered Asthma RElief (PREPARE). clinicaltrials.gov/ct2/show/NCT02995733 (first received 16 December 2016).
Nuhoglu 2001 {published data only}
    1. Nuhoglu Y, Bahceciler NN, Barlan IB, Mujdat Basaran M. The effectiveness of high-dose inhaled budesonide therapy in the treatment of acute asthma exacerbations in children. Annals of Allergy, Asthma & Immunology 2001;86(3):318-22. [PMID: ] - PubMed
O'Connor 2010 {published data only}
    1. O'Connor BJ, Kilfeather S, Cheung D, Kafé H, Blagden MD, Schlösser N, et al. Efficacy and safety of ciclesonide in patients with severe asthma: a 12-week, double-blind, randomized, parallel-group study with long-term (1-year) follow-up. Expert Opinion on Pharmacotherapy 2010;11(17):2791-803. [DOI: 10.1517/14656566.2010.526603] - DOI - PubMed
Papi 2022 {published data only}
    1. NCT03769090. A study to assess the efficacy and safety of budesonide/albuterol metered-dose inhaler (BDA MDI/PT027) in adults and children 4 years of age or older with asthma (MANDALA). clinicaltrials.gov/ct2/show/NCT03769090 (first received 7 December 2018).
    1. Papi A, Chipps BE, Beasley R, Panettieri RA, Israel E, Cooper M, et al. Albuterol-budesonide fixed-dose combination rescue inhaler for asthma. New England Journal of Medicine 2022;386(22):2071-83. - PubMed
Pedersen 2009 {published data only}
    1. Pedersen S, Engelstätter R, Weber HJ, Hirsch S, Barkai L, Emeryk A, et al. Efficacy and safety of ciclesonide once daily and fluticasone propionate twice daily in children with asthma. Pulmonary Pharmacology and Therapeutics 2009;22(3):214-20. - PubMed
Prentice 2017 {published data only}
    1. Prentice B, Homaira N, Jaffe A. Increased doses of inhaled corticosteroids during home management of asthma flare-ups do not reduce the need for systemic steroids. Journal of Paediatrics and Child Health 2017;53(9):915-7. - PubMed
Razi 2008 {published data only}
    1. Razi CH, Turktas I, Bakirtas A. Comparison of single 2000-microg dose treatment vs. sequential repeated-dose 500-microg treatments with nebulized budesonide in acute asthma exacerbations. Annals of Allergy, Asthma & Immunology 2008;100(4):370-6. [PMID: ] - PubMed
Rodrigo 1998 {published data only}
    1. Rodrigo G, Rodrigo C. Inhaled flunisolide for acute severe asthma. American Journal of Respiratory and Critical Care Medicine 1998;157(3 Pt 1):698-703. [PMID: ] - PubMed
Rodrigo 2005 {published data only}
    1. Rodrigo GJ. Comparison of inhaled fluticasone with intravenous hydrocortisone in the treatment of adult acute asthma. American Journal of Respiratory and Critical Care Medicine 2005;171(11):1231-6. [PMID: ] - PubMed
Schuh 2000 {published data only}
    1. Schuh S, Reisman J, Alshehri M, Dupuis A, Corey M, Arseneault R, et al. A comparison of inhaled fluticasone and oral prednisone for children with severe acute asthma. New England Journal of Medicine 2000;343(10):689-94. [PMID: ] - PubMed
Schuh 2006 {published data only}
    1. Schuh S, Dick PT, Stephens D, Hartley M, Khaikin S, Rodrigues L, et al. High-dose inhaled fluticasone does not replace oral prednisolone in children with mild to moderate acute asthma. Pediatrics 2006;118(2):644-50. [PMID: ] - PubMed
Sekerel 2005 {published data only}
    1. Sekerel BE, Sackesen C, Tuncer A, Adalioglu G. The effect of nebulized budesonide treatment in children with mild to moderate exacerbations of asthma. Acta Paediatrica 2005;94(10):1372-7. [PMID: ] - PubMed
Singhi 1999 {published data only}
    1. Singhi S, Banerjee S, Nanjundaswamy H. Inhaled budesonide in acute asthma. Journal of Paediatrics and Child Health 1999;35(5):483-7. [PMID: ] - PubMed
Svedmyr 1995 {published data only}
    1. Svedmyr J, Nyberg E, Asbrink Nilsson E, Hedlin G. Intermittent treatment with inhaled steroids for deterioration of asthma due to upper respiratory tract infections. Acta Paediatrica 1995;84(8):884-8. [PMID: ] - PubMed
Volovitz 1998 {published data only}
    1. Volovitz B, Bentur L, Finkelstein Y, Mansour Y, Shalitin S, Nussinovitch M, et al. Effectiveness and safety of inhaled corticosteroids in controlling acute asthma attacks in children who were treated in the emergency department: a controlled comparative study with oral prednisolone. Journal of Allergy and Clinical Immunology 1998;102(4 Pt 1):605-9. [PMID: ] - PubMed
Weinberger 2016 {published data only}
    1. Weinberger M. COUNTERPOINT: is escalation of the inhaled corticosteroid dose appropriate for acute loss of asthma control in an attempt to reduce need for oral corticosteroids in children? No. Chest 2016;150(3):490-2. - PubMed
Wilson 1990 {published data only}
    1. Wilson NM, Silverman M. Treatment of acute, episodic asthma in preschool children using intermittent high dose inhaled steroids at home. Archives of Disease in Childhood 1990;65(4):407-10. [PMID: ] - PMC - PubMed
Yousef 2012 {published data only}
    1. Yousef E, Hossain J, Mannan S, Skorpinski E, McGeady S. Early intervention with high-dose inhaled corticosteroids for control of acute asthma exacerbations at home and improved outcomes: a randomized controlled trial. Allergy and Asthma Proceedings 2012;33(6):508-13. - PubMed
    1. Yousef E, Hossain J, Mannnan S. Ineffectiveness of high-dose inhaled corticosteroids for control of pre-exacerbation asthma symptoms [abstract]. Journal of Allergy and Clinical Immunology 2011;127(2 Suppl 1):AB85.

Additional references

Barnes 1993
    1. Barnes NC, Marone G, Di Maria GU, Visser S, Utama I, Payne SL. A comparison of fluticasone propionate, 1 mg daily, with beclomethasone dipropionate, 2 mg daily, in the treatment of severe asthma. European Respiratory Journal 1993;6:877-85. [PMID: ] - PubMed
Cardet 2020
    1. Cardet JC, Busse PJ, Carroll JK, Casale TB, Coyne-Beasley T, Dixon-Williams S, et al. Adherence to adding inhaled corticosteroids to rescue therapy in a pragmatic trial with adults with asthma: a pilot study. Annals of Allergy, Asthma & Immunology 2020;124(5):487-93. - PMC - PubMed
Covidence [Computer program]
    1. Veritas Health Innovation Covidence. Version accessed 5 September 2022. Melbourne, Australia: Veritas Health Innovation. Available at covidence.org.
DerSimonian 1986
    1. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials 1986;7:177-88. - PubMed
Elbourne 2002
    1. Elbourne DR, Altman DG, Higgins JPT, Curtin F, Worthington HV, Vail A. Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology 2002;31(1):140-9. - PubMed
Fields 2001
    1. Fields AP. Meta-analysis of correlation coefficients: a Monte Carlo comparison of fixed- and random-effects methods. Psychological Methods 2001;6(2):161-80. - PubMed
Fuhlbrigge 2012
    1. Fuhlbrigge A, Peden D, Apter AJ, Mauger D, Teague WG, Blaisdell C, et al. Asthma outcomes: exacerbations. Journal of Allergy and Clinical Immunology 2012;129(3):S34-48. - PMC - PubMed
Gibson 2004
    1. Gibson PG, Powell H. Written action plans for asthma: an evidence-based review of the key components. Thorax 2004;59(2):94-9. [DOI: 10.1136/thorax.2003.011858] - DOI - PMC - PubMed
GINA 2015
    1. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention 2015. ginasthma.org/wp-content/uploads/2016/01/GINA_Report_2015_Aug11-1.pdf (accessed 17 February 2015).
GINA 2021
    1. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. ginasthma.org/wp-content/uploads/2021/05/GINA-Main-Report-2021-V2-WMS.pdf (accessed 8 August 2021).
GRADEpro GDT [Computer program]
    1. McMaster University (developed by Evidence Prime) GRADEpro GDT. Version accessed 23 September 2021. Hamilton (ON): McMaster University (developed by Evidence Prime). Available at gradepro.org.
Greenland 1985
    1. Greenland S, Robins JM. Estimation of a common effect parameter from sparse follow-up data. Biometrics 1985;41:55-68. - PubMed
Higgins 2003
    1. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60. [PMID: ] - PMC - PubMed
Higgins 2016
    1. Higgins JPT, Sterne JAC, Savović J, Page MJ, Hróbjartsson A, Boutron I, et al. A revised tool for assessing risk of bias in randomized trials. Cochrane Database of Systematic Reviews 2016;10 Suppl 1:29-30. [DOI: 10.1002/14651858.CD201601] - DOI
Higgins 2021
    1. Higgins JPT, Li T, Sterne J on behalf of the RoB 2 working group on crossover trials. Revised Cochrane risk of bias tool for randomized trials (RoB 2). Additional considerations for crossover trials (preliminary tool version, 18 March 2021). www.riskofbias.info/welcome/rob-2-0-tool/rob-2-for-crossover-trials (accessed prior to 4 September 2022).
Holt 2001
    1. Holt S, Suder A, Weatherall M, Cheng S, Shirtcliffe P, Beasley R. Dose-response relation of inhaled fluticasone propionate in adolescents and adults with asthma: meta-analysis. BMJ 2001;323(7307):253-6. - PMC - PubMed
Kupczyk 2014
    1. Kupczyk M, ten Brinke A, Sterk PJ, Bel EH, Papi A, Chanez P, et al. Frequent exacerbators - a distinct phenotype of severe asthma. Clinical and Experimental Allergy 2014;44(2):212-21. [DOI: 10.1111/cea.12179] - DOI - PubMed
Lemiere 2003
    1. Lemiere C, Bai T, Balter M, Bayliff C, Becker A, Boulet LP, et al. Adult Asthma Consensus Guidelines Update 2003. Canadian Respiratory Journal 2004;11(Suppl A):9A-33A. - PubMed
Marshall 2018
    1. Marshall IJ, Noel-Storr AH, Kuiper J, Thomas J, Wallace BC. Machine learning for identifying randomized controlled trials: an evaluation and practitioner’s guide. Research Synthesis Methods 2018;9(4):602-14. - PMC - PubMed
McDonald 2017
    1. McDonald S, Noel-Storr AH, Thomas J. Harnessing the efficiencies of machine learning and Cochrane Crowd to identify randomised trials for individual Cochrane reviews. In: Global Evidence Summit; 2017 Sep 13-16; Cape Town. 2017.
Mcivor 1998
    1. Mcivor RA, Pizzichini E, Turner MO, Hussack P, Hargreave FE, Sears MR. Potential masking effects of salmeterol on airway inflammation in asthma. American Journal of Respiratory and Critical Care Medicine 1998;158(3):924-30. [DOI: 10.1164/ajrccm.158.3.9802069] - DOI - PubMed
Noel‐Storr 2018
    1. Noel-Storr AH, Project Transform team. Cochrane Crowd: new ways of working together to produce health evidence. In: Evidence Live 2018; 2018 Jun 18-20; Oxford, UK. 2018.
Nwaru 2020
    1. Nwaru BI, Ekström M, Hasvold P, Wiklund F, Telg G, Janson C. Overuse of short-acting β2-agonists in asthma is associated with increased risk of exacerbation and mortality: a nationwide cohort study of the global SABINA programme. European Respiratory Journal 2020;55(4):1901872. [DOI: 10.1183/13993003.01872-2019] - DOI - PMC - PubMed
Ramsahai 2019
    1. Ramsahai JM, Hansbro PM, Wark PAB. Mechanisms and management of asthma exacerbations. American Journal of Respiratory and Critical Care Medicine 2019;199(4):423-32. [DOI: 10.1164/rccm.201810-1931CI] - DOI - PubMed
Reddel 2009
    1. Reddel HK, Taylor DR, Bateman ED, Boulet L-P, Boushey HA, Busse WW, et al. An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. American Journal of Respiratory and Critical Care Medicine 2009;180(1):59-99. [DOI: 10.1164/rccm.200801-060ST] - DOI - PubMed
RevMan Web 2022 [Computer program]
    1. The Cochrane Collaboration Review Manager Web (RevMan Web). Version 4.14.0. The Cochrane Collaboration, 2022. Available at revman.cochrane.org.
Risk of bias 2 resources webpage
    1. Current version of RoB 2. riskofbias.info (accessed prior to 22 September 2022).
Schünemann 2021
    1. Schünemann HJ, Higgins JPT, Vist GE, Glasziou P, Akl EA, Skoetz N, et al. Chapter 14: Completing ‘Summary of findings’ tables and grading the certainty of the evidence. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from training.cochrane.org/handbook/archive/v6.2.
Sears 2008
    1. Sears MR. Epidemiology of asthma exacerbations. Journal of Allergy and Clinical Immunology 2008;122(4):662-8. [DOI: 10.1016/j.jaci.2008.08.003] - DOI - PubMed
Soriano 2015
    1. Soriano JB, Abajobir AA, Abate KH, Abera SF, Agrawal A, Ahmed MB, et al. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Respiratory Medicine 2017;5(9):691-706. [DOI: 10.1016/S2213-2600(17)30293-X] - DOI - PMC - PubMed
Soriano 2017
    1. Soriano JB, Kendrick PJ, Paulson KR, Gupta V, Vos T, GBD Chronic Respiratory Disease Collaborators, et al. Prevalence and attributable health burden of chronic respiratory diseases, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Respiratory Medicine 2020;8(6):585-96. [DOI: 10.1016/S2213-2600(20)30105-3] - DOI - PMC - PubMed
Sterne 2019
    1. Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 2019;366:l4898. - PubMed
Stovold 2014
    1. Stovold E, Beecher D, Foxlee R, Noel-Storr A. Study flow diagrams in Cochrane systematic review updates: an adapted PRISMA flow diagram. Systematic Reviews 2014;3:54. - PMC - PubMed
Supplementary file 1
    1. Flemyng E, Kew K. DOSE-AST supplementary file data. Figshare URL https://doi.org/10.6084/m9.figshare.15797838.v1 2021. [DOI: 10.6084/m9.figshare.15797838.v1] - DOI
Supplementary file 2
    1. Flemyng E, Kew K. DOSE-AST RoB2 concensus data file. Figshare URL https://doi.org/10.6084/m9.figshare.15752415 2021. [DOI: 10.6084/m9.figshare.15752415] - DOI
Thomas 2017
    1. Thomas J, Noel-Storr AH, Marshall I, Wallace B, McDonald S, Mavergames C, et al. Living Systematic Review Network. Living Systematic Reviews: 2. Combining Human and Machine Effort. Journal of Clinical Epidemiology 2017;S0895-4356(17):30604-2. - PubMed
Volmer 2018
    1. Volmer T, Effenberger T, Trautner C, Buhl R. Consequences of long-term oral corticosteroid therapy and its side-effects in severe asthma in adults: a focused review of the impact data in the literature. European Respiratory Journal 2018;52(4):1800703. [DOI: 10.1183/13993003.00703-2018] - DOI - PubMed

References to other published versions of this review

Kew 2016
    1. Kew KM, Quinn M, Quon BS, Ducharme FM. Increased versus stable doses of inhaled corticosteroids for exacerbations of chronic asthma in adults and children. Cochrane Database of Systematic Reviews 2016, Issue CD007524. Art. No: CD007524. [DOI: 10.1002/14651858.CD007524.pub4] - DOI - PMC - PubMed
Quon 2009
    1. Quon BJ, FitzGerald M, Ducharme FM, Lasserson TJ, Lemière C. Increased versus stable doses of inhaled steroids for exacerbations of chronic asthma in adults and children. Cochrane Database of Systematic Reviews 2009, Issue 1. Art. No: CD007524. [DOI: 10.1002/14651858.CD007524] - DOI - PubMed
Quon 2010
    1. Quon BS, FitzGerald JM, Lemière C, Shahidi N, Ducharme FM. Increased versus stable doses of inhaled corticosteroids for exacerbations of chronic asthma in adults and children. Cochrane Database of Systematic Reviews 2010, Issue 12. Art. No: CD007524. [DOI: 10.1002/14651858.CD007524.pub3] - DOI - PubMed

Publication types

Substances

Associated data